Adoption of Biosimilars in Oncology

National Comprehensive Cancer Network® and Pfizer Global Medical Grants
Application or LOI Due Date
LOI due 9/9/20. Anticipated LOI Notification Date: October 28, 2020 Full Proposal Deadline: *December 9, 2020.
Brief Description

UPDATED INFORMATION: NCCN Pfizer Biosimilars Request for Proposal (RFP) Opportunity
Submit LOI by, Wednesday, September 9, 2020

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity in support of biosimilars in oncology. The intent of this RFP is to encourage organizations in the United States to submit initial Letters of Intent (LOIs) describing concepts that develop and validate enduring approaches to improve the safe, effective and efficient adoption of biosimilars in oncology. LOIs that directly measure increases in biosimilar use or improve safety, value and efficiency in both academic and/or community-based oncology practices will be prioritized. The sustainability and broad applicability of the approach, and its potential to add value to cancer care delivery, will be key factors in evaluating fundable projects. Update: Please note that this document can be accessed online at

NCCN views this collaboration with Pfizer as clear recognition of the advantages offered to the oncology community through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.

To be considered for funding, LOIs must be submitted by 11:59 pm ET on Wednesday, September 9, 2020. Please direct questions regarding this RFP to Nicole Kamienski at with the subject line, “2020 Biosimilars Project.”

View RFP for the NCCN Pfizer Biosimilars Research Grant Opportunity
Pfizer, Inc. Grant Application System